SELENOS and cancer: The major plasma biomarkers of Se status (total Se, selenoproteins, and LMW Se species) were accurately quantified in plasma from cancer patients before and after treatment with the three Se compounds (SS, SeMet, and MSC) administered at 400 μg Se/day for 28 days (Table 3).